NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions
Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat...